Over the past few years, GLP-1 medications have transformed obesity treatment across Europe. These drugs, originally developed for type 2 diabetes, have shown powerful weight-loss effects by regulating appetite, metabolism, and blood sugar.Best GLP-1 Weight Loss Drugs in Europe
Today, medications such as semaglutide and tirzepatide are widely prescribed for weight management, and several next-generation drugs are currently being developed.
This guide explains the best GLP-1 weight-loss drugs in Europe in 2026, including how they work, how effective they are, and which ones are currently available.
What Are GLP-1 Weight Loss Drugs?
GLP-1 medications mimic a natural hormone called glucagon-like peptide-1.
This hormone helps regulate several metabolic processes:
- Appetite control
- Blood sugar regulation
- Insulin production
- Digestion speed
By activating GLP-1 receptors, these drugs help people feel full faster and eat fewer calories.
Because of these effects, GLP-1 medications can produce significant weight loss without surgery.
Demand has surged across Europe, even leading to supply shortages in some countries due to the popularity of these treatments.Best GLP-1 Weight Loss Drugs in Europe
1. Semaglutide (Wegovy)
Semaglutide is currently one of the most widely prescribed weight-loss medications in Europe.
It is sold under different brand names:
- Wegovy (for weight loss)
- Ozempic (for diabetes)
- Rybelsus (oral tablet)
Wegovy is specifically approved for chronic weight management.Best GLP-1 Weight Loss Drugs in Europe
How It Works
Semaglutide activates the GLP-1 receptor, which:
- Suppresses appetite
- Slows stomach emptying
- Improves insulin release
Weight Loss Results
Clinical trials show:
- Average weight loss: about 15% of body weight
- Treatment period: around 68 weeks
For many patients, this means losing 30–50 pounds or more depending on starting weight.Best GLP-1 Weight Loss Drugs in Europe
Availability in Europe
Wegovy is approved across the European Union and increasingly prescribed for obesity treatment.
Typical cost in Europe:
- €200 – €350 per month
2. Tirzepatide (Mounjaro)
Tirzepatide represents the next generation of metabolic therapies.
Unlike traditional GLP-1 drugs, tirzepatide activates two hormone pathways:
- GLP-1
- GIP (glucose-dependent insulinotropic polypeptide)
Because of this dual-hormone effect, tirzepatide is often considered more powerful than earlier medications.
Weight Loss Results
Clinical trials showed:
- Up to 22.5% body weight reduction in 72 weeks
This makes tirzepatide one of the most effective weight-loss medications currently available.Best GLP-1 Weight Loss Drugs in Europe
Availability
Tirzepatide is approved in Europe for type 2 diabetes and is increasingly used for weight management under medical supervision.Best GLP-1 Weight Loss Drugs in Europe
Average cost:
- €250 – €400 per month
3. Liraglutide (Saxenda)
Before semaglutide and tirzepatide, liraglutide was the most commonly prescribed weight-loss injection.
It is marketed under the brand name Saxenda.Best GLP-1 Weight Loss Drugs in Europe
How It Works
Liraglutide is also a GLP-1 receptor agonist, but it requires daily injections rather than weekly dosing.Best GLP-1 Weight Loss Drugs in Europe
Weight Loss Results
Clinical studies show:
- 5–8% body weight loss on average
While effective, liraglutide is generally considered less powerful than newer GLP-1 medications.Best GLP-1 Weight Loss Drugs in Europe
Availability
Saxenda is widely available in Europe but is gradually being replaced by more effective treatments.
Typical cost:
- €200 – €300 per month
4. Retatrutide (Future Weight Loss Drug)
Retatrutide is one of the most exciting experimental obesity medications currently being studied.Best GLP-1 Weight Loss Drugs in Europe
It uses a triple-hormone mechanism, targeting:
- GLP-1
- GIP
- Glucagon receptors
This triple action may increase metabolism while suppressing appetite.
Clinical Trial Results
Early studies show:
- Up to 24% weight loss in 48 weeks
These results are among the strongest ever reported for an anti-obesity drug.
Availability
Retatrutide is still in Phase 3 clinical trials and is not yet approved in Europe.
Experts expect possible approval around 2027–2028 if trials remain successful.Best GLP-1 Weight Loss Drugs in Europe
5. Future GLP-1 Drugs Coming to Europe
Several next-generation therapies are expected to reach the European market soon.
CagriSema
CagriSema is a combination drug that combines:
- Semaglutide
- Cagrilintide (an amylin analog)
Early trials suggest:
- 15–20% weight loss
Regulatory submissions are expected soon.
Oral GLP-1 Medications
New pill versions of GLP-1 drugs are also being developed.
Examples include:
- High-dose oral semaglutide
- Orforglipron
These medications could make weight-loss therapy easier for people who prefer not to use injections.
GLP-1 Weight Loss Drug Comparison
| Medication | Type | Average Weight Loss | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% | Approved |
| Tirzepatide (Mounjaro) | GLP-1 + GIP | ~22% | Approved |
| Liraglutide (Saxenda) | GLP-1 agonist | ~5–8% | Approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% | Clinical trials |
Why GLP-1 Drugs Are So Popular
GLP-1 medications have become extremely popular for several reasons.
Significant Weight Loss
These medications produce weight loss results far greater than older diet drugs.
Improved Metabolic Health
They can also improve:
- Blood sugar levels
- Insulin sensitivity
- Blood pressure
- Cholesterol levels
Reduced Risk of Heart Disease
Some GLP-1 medications have also shown cardiovascular benefits, making them valuable treatments for patients with metabolic disorders.
Who Qualifies for GLP-1 Weight Loss Drugs?
Doctors typically prescribe these medications for people who meet certain criteria.
Common eligibility guidelines include:
- BMI of 30 or higher
- BMI 27+ with obesity-related conditions
Examples of related conditions include:
- Type 2 diabetes
- High blood pressure
- Sleep apnea
- Fatty liver disease
Medical supervision is required before starting treatment.
Cost of GLP-1 Medications in Europe
Prices vary depending on country and dosage.
Typical monthly costs include:
| Drug | Average Cost |
|---|---|
| Wegovy | €200 – €350 |
| Saxenda | €200 – €300 |
| Mounjaro | €250 – €400 |
In many European countries, these medications are not fully covered by public healthcare systems, meaning patients often pay privately.
Are GLP-1 Weight Loss Drugs Safe?
GLP-1 medications are generally considered safe when prescribed by healthcare professionals.
Common side effects include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Reduced appetite
These symptoms usually improve as the body adapts to the medication.
However, medical supervision is important to ensure safe use.
Frequently Asked Questions
What is the strongest GLP-1 drug for weight loss?
Tirzepatide currently produces the highest weight-loss results among approved medications.
Is Wegovy available in Europe?
Yes. Wegovy is approved in the European Union and widely prescribed for obesity treatment.
Is Ozempic the same as Wegovy?
Both contain semaglutide, but Wegovy uses a higher dose specifically approved for weight management.
What new weight-loss drugs are coming soon?
Future medications include retatrutide, CagriSema, and oral GLP-1 drugs currently in development.
Conclusion
GLP-1 medications have dramatically changed the way obesity is treated across Europe.
Among the current options:
- Semaglutide (Wegovy) remains the most established treatment
- Tirzepatide (Mounjaro) offers stronger weight-loss results
- Liraglutide (Saxenda) remains an older but still effective option
Meanwhile, future drugs like retatrutide may push weight-loss results even further.
As research continues, GLP-1 therapies are expected to play an increasingly important role in managing obesity and metabolic health across Europe.